Last reviewed · How we verify

NCT04634617

Pelvic Floor Dysfunction and Quality of Life in Uterine Cancer Survivors

Active, enrolled Last updated 10 November 2025
What this trial tests

trial testing Questionnaire Administration in Endometrial Carcinoma in 310 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
9 January 2020
Primary endpoint
11 April 2027
11 April 2027

Quick facts

Lead sponsorM.D. Anderson Cancer Center
StatusActive, enrolled
Study typeOBSERVATIONAL
Enrollment310
Start date9 January 2020
Primary completion11 April 2027
Estimated completion11 April 2027
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

M.D. Anderson Cancer Center — full company profile →

Who can join

18 and older, female only, with Endometrial Carcinoma or Malignant Uterine Neoplasm. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This trial studies pelvic floor dysfunction and quality of life in uterine cancer survivors. Using questionnaires may help researchers learn more about the sexual function and quality of life in uterine cancer survivors.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Questionnaire Administration

Trials testing the same drug.

Other recruiting trials for Endometrial Carcinoma

Currently open trials in the same condition.

Other M.D. Anderson Cancer Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04634617.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing